What progress has been made in my country's new crown vaccine research and development

What progress has been made in my country's new crown vaccine research and development

What progress has been made in China's new crown vaccine research and development? What progress has been made in my country's new crown vaccine research and development

On September 13, the official website of the National Health Commission showed that from 0-24 on September 12, 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps reported 49 new confirmed cases
.

Among them, 27 were imported cases and 22 were local cases, all in Fujian

At several press conferences held by the State Council’s Joint Prevention and Control Mechanism a few days ago, Zheng Zhongwei, the leader of the research team’s vaccine research and development team and director of the Science and Technology Development Center of the National Health Commission, and other experts have repeatedly called for the "Import, internal non-proliferation" is still the top priority of epidemic prevention and control, and continuous promotion of new crown vaccination is still the focus of work
.

So, what kind of effective protection can my country's new crown vaccine provide for vaccinators, and what progress has been made?

State Council

3 inactivated vaccines and 1 adenovirus vector vaccine were approved for listing with conditions

3 inactivated vaccines and 1 adenovirus vector vaccine were approved for listing with conditions

At the beginning of 2020, China has deployed five technical routes for the development of new crown vaccines, including inactivated vaccines, adenovirus vector vaccines, recombinant protein vaccines, attenuated influenza virus vector vaccines and nucleic acid vaccines
.

"The five technical routes are done together, and the main purpose is to ensure the success rate
.

" According to Zheng Zhongwei, so far, the five technical routes have achieved full coverage of clinical trials: 3 inactivated vaccines have been listed conditionally by the State Food and Drug Administration 2 models were approved by the State Food and Drug Administration for emergency use; 1 recombinant protein vaccine was approved by the State Food and Drug Administration for emergency use, 3 models were undergoing phase III clinical trials, and 5 models were undergoing phase I, Phase II clinical trials; 1 adenovirus vector vaccine has been approved by the State Food and Drug Administration for conditional marketing, and 3 models are undergoing phase I and II clinical trials; attenuated influenza virus vector vaccines are undergoing phase II clinical trials and are preparing for overseas In terms of nucleic acid vaccines, China has one mRNA vaccine and one DNA vaccine, and both have recently obtained approvals for phase III clinical trials abroad.

Sequential immunization studies of vaccines with different technical routes are being carried out

Sequential immunization studies of vaccines with different technical routes are being carried out

With the rebound of the global epidemic, sequential immunization research is currently receiving more and more attention
.

Zheng Zhongwei introduced that at the August 2 expert demonstration meeting organized by the new crown vaccine research and development team, the experts clearly recommended support for the development of sequential immunization research and pilot work of vaccines with different technical routes

It is understood that sequential immunization refers to the interval vaccination of vaccines of different technical routes, that is, the "mixed" in the mouth of the people, so as to achieve high protective efficacy and lasting immunity that cannot be successfully achieved by a single-variety vaccine
.

"At present, some R&D institutions in China are carrying out related sequential immunization research work at home and abroad.
Only after obtaining sufficient scientific data on safety and immunogenicity or effectiveness, can we propose a proposal for sequential immunization work for large-scale populations.
Expert advice
.

" Zheng Zhongwei said

Vaccination can effectively prevent the disease from turning into severe or critical illness

Vaccination can effectively prevent the disease from turning into severe or critical illness

The protective effect of any vaccine against infectious diseases cannot be 100%, and the same is true for all types of new crown vaccines that are being used on a global scale
.

In this regard, Zheng Zhongwei explained that after vaccination, the level of neutralizing antibodies will gradually decrease over time, which is also a normal state of vaccination

Regarding the mutation of the new coronavirus, which is widely concerned by the society, Zheng Zhongwei said that since the outbreak, especially since the emergence of mutant strains, China has been carrying out a series of research and development work on vaccines against various mutant strains
.

Including vaccine research and development units that have carried out research on inactivated vaccines of gamma and delta strains, preclinical studies have been completed, and some units have submitted clinical trial application materials to the Drug Evaluation Center; For the research of high-value recombinant protein vaccines, some units have submitted clinical trial application materials to the Drug Evaluation Center on a rolling basis; for the research and development of adenovirus vector vaccines and nucleic acid vaccines against beta strains and delta strains, some units have completed animal validity And safety experiments are preparing to apply for clinical trials

"With such preparations, even if the virus mutates severely in the future and completely escapes the preventive effect of the vaccines currently produced, we can quickly develop and produce new vaccines on a large scale, so as to be prepared
.

" Zheng Zhongwei said

As of September 12, 2021, 31 provinces (autonomous regions and municipalities directly under the Central Government) and Xinjiang Production and Construction Corps have reported a total of 2.

(Our newspaper reporter Jin Zhenya, Beijing, September 13)

Focus on the new crown pneumonia epidemic